Alnylam Pharmaceuticals
ALNY
#429
Rank
A$81.76 B
Marketcap
A$618.86
Share price
2.02%
Change (1 day)
55.45%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): A$0.15

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$0.13. In 2023 the company made an earnings per share (EPS) of A-$5.29 an increase over its 2022 EPS that were of A-$13.93.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$0.15
2023A-$5.29-62%
2022A-$13.9329.03%
2021A-$10.80-3.36%
2020A-$11.17-8.48%
2019A-$12.217.67%
2018A-$11.3439.74%
2017A-$8.1112.94%
2016A-$7.1838.84%
2015A-$5.17-32.88%
2014A-$7.71259.44%
2013A-$2.14-31.25%
2012A-$3.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
A-$1.87-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
A$65.15 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$4.11-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.36-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.09-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$11.04 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$5.56 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
A$0.94 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel